Element Nutritional Sciences Announces Closing of $3.5 Million Financing

Rhea-AI Summary

Element Nutritional Sciences announced the successful closure of its short form prospectus offering, raising $3.5 million through the sale of 14 million common shares at $0.25 each. The offering was led by Canaccord Genuity Corp., which received an 8% cash commission and broker warrants. The net proceeds will be used for marketing, research and development, and general working capital. Element specializes in science-based products for those over 50, with a key product, Rejuvenate™, aimed at combating muscle loss due to aging.

Positive

• Raised $3.5 million through the issuance of 14 million shares.
• Proceeds will enhance marketing and R&D efforts.

Negative

• None.

Not for distribution to U.S. news wire services or dissemination in the United States.

BURLINGTON, Ontario--(BUSINESS WIRE)-- Element Nutritional Sciences Inc. (CSE:ELMT; OTCQB:ELNSF; FRANKFURT:93X) (the “Company” or “Element”) is pleased to announce that it has closed its previously announced short form prospectus offering raising gross proceeds of $3.5 million for the Company through the issuance of 14,000,000 common shares of the Company (the “Shares”) at a price of $0.25 per Share (the “Offering”).

Canaccord Genuity Corp. (the “Agent”) acted as agent and sole bookrunner in connection with the Offering. The Agent received a cash commission equal to 8.0% of the gross proceeds from the sale of Shares pursuant to the Offering. The Agent also received broker warrants (each, a “Broker Warrant”) equal to 8.0% of the number of Shares sold pursuant to the Offering. Each Broker Warrant entitles the Agent to purchase one Share at a price of $0.25 per Share for a period of 24 months following the closing of the Offering.

The Company intends to use the net proceeds from the Offering primarily for marketing expenses, research and development and general working capital. Further details regarding the Offering are contained in the Company's short form prospectus dated April 28, 2022.

About Element

Element is an innovative and research driven Canadian nutraceutical company specializing in the development of science-based products for the global consumer packaged goods market, with a portfolio focused specifically on men and women over the age of 50. Element’s lead product, Rejuvenate™, is a proprietary formulation that is clinically proven to assist in the rebuilding, restoration and rejuvenation of natural loss of muscle mass due to aging or other medical conditions. Element also offers JAKTRX™, an elite brand of performance supplements. Element was founded in 2015 and is located in Burlington, Ontario.

To learn more about Element, visit elmtinc.com.

More information about Rejuvenate™ can be found at: www.rejuvenatemuscle.com

More information about JAKTRX™ and Promino™ can be found at: www.jaktrx.com

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to the anticipated use of the net proceeds of the Offering. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; expectations regarding the size of the United States and Canadian health, nutraceutical and wellness markets and changing consumer habits; the viability of the Company’s products; availability of distribution channels for the Company’s product offerings; the ability of the Company to successfully achieve its business objectives; plans for expansion; successful development of the Company’s proposed products; the presence of laws and regulations that may impose restrictions or recalls on the sale of the Company’s products in the United States and Canada; customer and distributor relations; fluctuations in securities markets; and the inability of the Company to obtain adequate insurance to cover risks and hazards. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220506005501/en/

Stuart Lowther

Chairman, CEO and President

ir@elementnutrition.com

416-467-5229

Marc Charbin

Investor Relations

ir@elementnutrition.com

416-467-5229

Source: Element Nutritional Sciences Inc.

FAQ

What recent financial milestone did ELNSF achieve?

Element Nutritional Sciences raised $3.5 million through a share offering.

How many shares did ELNSF issue in the recent offering?

Element issued 14 million common shares at $0.25 per share.

Who managed the recent offering for ELNSF?

Canaccord Genuity Corp. acted as the agent and sole bookrunner for the offering.

What will ELNSF use the proceeds from the offering for?

The funds will primarily support marketing, research, development, and working capital.